Wegovy (semaglutide)
A prescription medicine for weight management. Whether it’s right for you is a clinical decision, made from your health information and your baseline blood test.
Available in
From £59 / month First month for new customers on a 12-month plan, at the starting dose. Everything included.
After month one: from £139 / month at the starting dose. 12-month plan total from £1,727 (13 payments). Billed every 28 days. Full pricing by dose
Subject to clinical approval
- Part of the SheMed Group: over 100,000 people supported across the UK
- Blood tests, clinician reviews and support included
- Delivered the next working day, discreetly packaged
What Wegovy is
Wegovy contains semaglutide, a GLP-1 receptor agonist: a medicine that acts on the hormone system involved in appetite regulation. It’s made by Novo Nordisk and licensed in the UK for weight management in adults.
Form
Pre-filled pen
Frequency
Once a week
Dose
Starts at 0.25mg, adjusted by your clinician
Monthly price by dose and plan
Every price includes the whole plan: the medicine, your blood tests, clinical reviews, support and delivery.
Billed every 28 days: a 12-month plan is 13 payments. Rolling plans: cancel with at least 5 days’ notice before your next payment date. Fixed plans: cancellation terms are shown before you commit.
| Dose | Rolling monthly | 3-month plan | 6-month plan | 12-month plan |
|---|---|---|---|---|
| 0.25mg (starting dose)* | £79 | £69 | £64 | £59 |
| 0.5mg | £139 | £139 | £139 | £139 |
| 1mg | £139 | £139 | £139 | £139 |
| 1.7mg | £159 | £159 | £159 | £159 |
| 2.4mg | £159 | £159 | £159 | £159 |
| 7.2mg | £239 | £239 | £239 | £239 |
*Starting-dose plan prices are first-month prices for new customers. You can cancel per the plan terms, set out before you commit.
In its highest-dose clinical trial (STEP UP), adults taking semaglutide 7.2mg weekly who stayed on treatment lost an average of 20.7% of their body weight over 72 weeks, compared with 2.4% for those making diet and lifestyle changes alone. Average trial results are not a prediction of individual results.1,2
In the same trial, 31.2% of people taking 7.2mg lost 25% or more of their body weight, compared with 0% of those on placebo.2
In a post hoc analysis reported by Novo Nordisk (May 2026), the roughly one in four people on the 7.2mg dose who responded early (losing 15% or more by week 24) averaged 27.7% weight loss at 72 weeks.3
How it compares
A factual comparison of the treatments available through the service. Which one suits you depends on your health, your history and your blood test.
| WegovyWeekly pen | Wegovy PillDaily tablet | MounjaroWeekly pen | FoundayoDaily tablet | |
|---|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Tirzepatide | Orforglipron |
| Form | Pre-filled pen, once a week | Tablet, once a day | Pre-filled pen, once a week | Tablet, once a day |
| Starting dose | 0.25mg | 1.5mg | 2.5mg | 0.8mg |
| From | £59 / month | £69 / month | £154 / month | £64 / month |
| This page | View Wegovy Pill | View Mounjaro | View Foundayo |
| WegovyWeekly pen | Wegovy PillDaily tablet | MounjaroWeekly pen | FoundayoDaily tablet | |
|---|---|---|---|---|
| Average weight loss in its main trial* | 18.7% (7.2mg, STEP UP, 72 weeks) | 13.6% (25mg, OASIS 4, 64 weeks) | 20.9% (15mg, SURMOUNT-1, 72 weeks) | 11.2% (highest trial dose, ATTAIN-1, 72 weeks) |
*Averages from each medicine's own main trial on its main analysis: separate trials with different designs and durations, not head-to-head comparisons, and not a prediction for any one person. Placebo groups lost 2.1% to 3.9% across these trials. Each medicine's page carries its fuller results and sources.
Who may be eligible
Always a clinical decision: a clinician reviews your blood test and health information before prescribing anything.
May be considered
- Adults with a BMI of 30 or over
- Adults with a BMI of 27 or over alongside a weight-related health condition
Not suitable
- In pregnancy, or when trying to conceive
- Under 18
- With certain medical histories: the clinician screens for these, and the patient information leaflet carries the full list
Side effects
The most commonly reported side effects are digestive: nausea, diarrhoea, constipation and vomiting, most often while the dose is increasing. The patient information leaflet carries the full list, including rarer serious side effects and when to seek urgent help: read it before starting. Your clinician reviews side effects with you during care, and you can report them through the MHRA Yellow Card scheme.
Questions, asked and answered
Is Wegovy available through HeMed?
Yes, where a clinician judges it appropriate. Wegovy is one of four treatments available through the service; the clinical review and your blood test decide what’s recommended.
How much is the HeMed plan with Wegovy?
From £59 a month for new customers on a 12-month plan at the starting dose. The table above lists every dose and plan; every price includes the whole plan.
Do I need a prescription?
Yes. Wegovy is a prescription-only medicine. A clinician reviews your health information and blood test, and prescribes only if treatment is appropriate.
Can I change treatment later?
Yes, if it’s clinically right for you. Your clinician can reassess your plan at any review.
See where you stand
The eligibility check takes a few minutes. Every plan starts with a blood test, so the decisions come from your numbers.
Get startedSources (4)
- Garvey WT et al.; STEP UP investigators. Once-weekly semaglutide 7.2 mg in adults with obesity. The Lancet Diabetes and Endocrinology, 2025;13(11):949-963. doi.org/10.1016/S2213-8587(25)00226-8.
- Wegovy 7.2mg, Summary of Product Characteristics (STEP UP results, Table 11). Novo Nordisk Limited. medicines.org.uk/emc/product/102093/smpc. Accessed 7 September 2026.
- Novo Nordisk A/S. Higher dose Wegovy demonstrates nearly 28% weight loss in early responders (STEP UP post hoc analyses, European Congress on Obesity). Company press release, 12 May 2026. globenewswire.com (Novo Nordisk A/S).
- Comparison table trial figures (main-analysis averages; separate trials): STEP UP doi.org/10.1016/S2213-8587(25)00226-8; SURMOUNT-1 doi.org/10.1056/NEJMoa2206038; OASIS 4 doi.org/10.1056/NEJMoa2500969; ATTAIN-1 doi.org/10.1056/NEJMoa2511774.
Numbered markers in the page text link to these entries. Trial figures are averages from separate trials, not a prediction for any one person.